ClinicalTrials.gg
RecruitingNCT07461454Updated May 26, 2026

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

A Phase 3 interventional study of YL202 and Eribulin in Locally Advanced or Metastatic Breast Cancer, sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
376
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.

Planned enrollment
316th of 1,519
376 · median 120
Started
2026
with 184 others
Phase 3
331 of 1,928
120 open now
Primary completion
2027-12
later than 755 of 1,063 live
Registered
1,769th of 1,928
by date

Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 316th largest by planned enrollment of the 1,519 interventional ones that give a count, is one of 185 that started in 2026, is one of 331 in phase 3, reaches primary completion later than 755 of the 1,063 other live ones, and was the 1,769th registered.

Breast Neoplasms

14,832 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

861 more — sign in →

All 866 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,928 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

The study will evaluate the safety and efficacy of YL202, when compared with treatment of physician's choice (eribulin, capecitabine, vinorelbine, gemcitabine or sacituzumab govitecan) in participants with unresectable locally advanced, recurrent or metastatic hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer who had failed at least one line of chemotherapy.

03

Conditions studied

  • Locally Advanced or Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have been informed of the study before the start of the study and voluntarily sign name and date on the form.
  2. and/or cytologically confirmed locally advanced or HR+/- breast cancer who are not candidates for curative surgery or radiotherapy.
  3. Patients who had failed at least one in unresectable locally advanced, recurrent, or metastatic stage.
  4. Have at least 1 extracranial as a target lesion per 1.1.
  5. Tumor tissue samples can be provided at the time of diagnosis of locally advanced or metastatic tumors.
  6. (ECOG) performance status score of 0 to 1.
  7. Have Adequate organ and bone marrow function within 7 days prior to the first dose.
  8. Female patients of must agree to use highly effective from screening throughout the duration of the study and for at least 6 months after the last dose of study drug.
  9. Have a expected survival ≥ 3 months.
  10. Have ability and willingness to comply with protocol-specified visits and procedures.

Exclusion criteria

Exclusion Criteria:

  1. Have prior treatment with an agent targeting HER3.
  2. Have prior treatment with topoisomerase I inhibitor or an ADC that consists of topoisomerase I inhibitor.
  3. Have insufficient for prior anticancer therapy prior to first dose of the study drug.
  4. Have major surgery (excluding diagnostic surgery) within 4 weeks prior to the first dose of study drug or anticipation of major surgery during the study.
  5. or carcinomatous meningitis, spinal cord compression.
  6. Have uncontrolled or cardiovascular and cerebrovascular disease.
  7. Have clinically significant concomitant pulmonary diseases.
  8. Have uncontrolled pleural effusion, abdominal effusion.
  9. Have serious infection within 4 weeks prior to the first dose.
  10. Have a history of severe reactions to the drug substance, inactive ingredients in the drug product, or other monoclonal antibodies.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
376 participants (estimated)

Study arms

  • Experimental
    YL202

    Drug: YL202

  • Active comparator
    Treatment of Physician's Choice (TPC)

    TPC,Eribulin, capecitabine, gemcitabine, vinorelbine or sacituzumab govitecan

    Drug: Eribulin · Drug: Capecitabine · Drug: Gemcitabine · Drug: Vinorelbine · Drug: Sacituzumab govitecan

Interventions

  • DrugYL202

    IV infusion on day 1 of each 21 day cycle

  • 1.4 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle

  • 1000 or 1250 mg/m2, po, bid, from day 1 to Day 14 of each 21 day cycle

  • 1000 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle

  • 25 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle

  • 10 mg/kg, IV infusion on day 1 and Day 8 of each 21 day cycle

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) assessed by BIRC per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

    PFS is defined as time from randomization until disease progression or death due to any cause.

    Time frame: up to 18 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as time from randomization until the date of death due to any cause.

    Time frame: up to 36 months

  2. Progression-free survival (PFS) assessed by the investigators per RECIST V 1.1

    PFS is defined as time from randomization until disease progression or death due to any cause.

    Time frame: up to 18 months

  3. Objective Response Rate (ORR)

    Objective response rate is defined as the proportion of participants who have a CR or PR, as determined by the BICR/Investigator assessment, per RECIST 1.1.

    Time frame: up to 18 months

  4. Duration of Response (DoR)

    Duration of response is defined as the time from the date of first documented confirmed response until disease progression, as determined by BICR/Investigator assessment or death due to any cause.

    Time frame: up to 18 months

  5. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants who have a CR, PR or SD, per RECIST 1.1, as determined by BICR/Investigator assessment, per RECIST 1.1.

    Time frame: up to 18 months

  6. Adverse Events (AEs)

    Incidence and severity of AEs and clinically significant abnormal laboratory findings.

    Time frame: up to 36 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 21 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 10, 2026
StartActual
Mar 17, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07461454
Responsible party
Sponsor
First posted
Mar 10, 2026
Start date
Mar 17, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
May 26, 2026

Study contacts

Medilink Study Team
Contact
clinicaltrials@medilinkthera.com
+86 0512-62858368

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beruzatatug pelitecan

Start the discussion